Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 27, 2003
Business Overview: Henry Schein is the largest distributor of healthcare products and services to office-based practitioners in North America and Europe. Operations are divided into two segments: Healthcare Distribution (dental, medical, veterinary, and international) and Technology (practice management software).
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 27, 2003 |
Nine Months Ended Sep 27, 2003 |
Nine Months Ended Sep 28, 2002 |
|---|---|---|---|
| Net Sales | $892,718 | $2,406,881 | $2,077,598 |
| Gross Profit | $251,500 | $673,446 | $587,258 |
| Gross Margin | 28.2% | 28.0% | 28.3% |
| Operating Income | $76,400 | $174,635 | $146,472 |
| Net Income | $44,347 | $101,968 | $87,024 |
| Diluted EPS | $0.99 | $2.27 | $1.94 |
| Cash from Operations | N/A | $18,091 | $65,650 |
| Cash & Equivalents | $92,857 | $92,857 | $200,651 (Dec 2002) |
| Total Debt | $256,221 | $256,221 | $247,013 (Dec 2002) |
Note: Total Debt includes current maturities ($4,357) and long-term debt ($245,389) as of September 27, 2003.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 17.6% ($133.6 million) for the quarter and 15.8% ($329.3 million) for the nine-month period compared to the prior year. Growth was driven by the Healthcare Distribution segment (17.9% quarterly increase), specifically Medical (17.5%) and International (33.9%) divisions.
- Profitability: Operating income rose 18.9% for the quarter and 19.2% for the nine-month period. However, gross profit margins declined slightly (28.2% vs. 28.5% for the quarter) due to sales mix changes in medical and international businesses.
- Cash Flow: Operating cash flow decreased significantly to $18.1 million for the nine months ended September 27, 2003, compared to $65.7 million in the prior year. This was primarily due to increased trade receivables and inventory levels supporting higher sales volume.
- Acquisitions & Divestitures: The company acquired Hager Dental GmbH (Germany) and Colonial Surgical Supply (US). It divested PMA Bode GmbH (Germany), recording a $2.0 million loss on the sale of this discontinued operation.
- Share Repurchases: The company repurchased 1,283,500 shares of common stock for $57.7 million during the nine-month period.
Guidance, Outlook, and Risks
- Capital Allocation: Management expects to invest approximately $6.0 million in capital projects during the fourth quarter to modernize facilities and computer infrastructure.
- Liquidity: The company maintains a $200 million revolving credit facility with no borrowings outstanding as of September 27, 2003. Management believes existing cash, marketable securities, and credit facilities are sufficient for foreseeable needs.
- Seasonality: Sales and profits are typically higher in the third and fourth quarters due to seasonal purchasing patterns and year-end promotions.
- Risk Factors:
- Competition: High competition from manufacturers and other distributors; risk of manufacturers bypassing distributors.
- Regulatory: Subject to federal and foreign laws regarding pharmaceuticals and medical devices.
- Legal Proceedings: Approximately 45 product liability cases pending (mostly latex glove allergies); a Texas class action regarding software certification was decertified by the Supreme Court but plaintiffs have filed amended motions. A New Jersey class action regarding vaccine sales is ongoing.
- International Risks: Exposure to foreign currency fluctuations and regulatory changes in international markets.
Investor Verification Checklist
- Working Capital Efficiency: Verify the sustainability of the increased accounts receivable (47.4 days) and inventory levels, which significantly reduced operating cash flow.
- Margin Pressure: Monitor gross margin trends, particularly in the Medical and International segments where mix changes have caused slight declines.
- Legal Exposure: Track the status of the Texas class action (amended certification motion) and the New Jersey vaccine class action for potential financial impact.
- Debt Structure: Note the recent exchange of fixed-rate senior notes ($230 million) to variable rates (LIBOR + spread), increasing interest rate sensitivity.
- Acquisition Integration: Assess the performance of recent acquisitions (Hager Dental, Colonial Surgical) and the impact of the divestiture on future international revenue.